Vanguard Capital Management
AXSM icon

Vanguard Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Vanguard Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$481M Buy
1,965,086
+27,334
+1% +$5.93M 0.01% 724
2026
Q1 		$328M Buy
+1,937,752
New +$335M 0.01% 814

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Vanguard Capital Management's AXSM Position: Q2 2026 in Review

Vanguard Capital Management increased its Axsome Therapeutics (AXSM) stake by 1.4% in Q2 2026, buying an estimated $5.93M and bringing the position to 1,965,086 shares worth $481M. The position accounts for 0.01% of the portfolio, ranked #724.

Vanguard Capital Management first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. 461 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Vanguard Capital Management held 1,965,086 shares of Axsome Therapeutics worth $481M as of Q2 2026.
  • Vanguard Capital Management bought 27,334 Axsome Therapeutics shares in Q2 2026, an estimated $5.93M.
  • Axsome Therapeutics made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #724 holding.
  • Vanguard Capital Management first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 461 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.